Share on LinkedInTweet about this on TwitterPin on PinterestShare on FacebookShare on Google+

VIVUS, Inc. announced today that a new study demonstrates that effective medical treatment providing 10% to 15% weight loss could lead to significant improvements in Medicare spending by reversing or reducing significant health consequences such as type 2 diabetes, hypertension and dyslipidemia in obese or overweight patients.

See more here:
Study projects potential impact of FDA-approved anti-obesity medications on Medicare spending

Share on LinkedInTweet about this on TwitterPin on PinterestShare on FacebookShare on Google+